meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cabozantinib
nivolumab based treatment
nivolumab alone
versus all
vs mTOR inhibitors
vs everolimus
vs VEGF(R) inhibitor
vs cabozantinib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab based treatment
nivolumab based treatment
atezolizumab plus cabozantinib
nivolumab alone
Comparator:
vs cabozantinib;
vs everolimus;
Risk of bias:
low;
some concerns;
high;
NA;